Latest News and Press Releases

Each panel focuses on distinct areas of tumor biology and response to therapy which are of greatest interest to translational and clinical researchers Simplifies biomarker assay development and...

The OncoSignature® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted...

MARLBOROUGH, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, today announced the appointment of Dr. Ehab A. El-Gabry as the company’s...

Company to present industry’s first 100-plex, whole slide dataset for deep spatial phenotyping of the tumor microenvironmentThe Company will also showcase its novel protein chemistry to accelerate...

MARLBOROUGH, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced the appointment of Marilee Moy as Chief People...

MARLBOROUGH, Mass. and MINNEAPOLIS, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, and Bio-Techne (NASDAQ: TECH), a global life sciences...

-Company previews an integrated suite of solutions, including the new PhenoCycler™-Fusion System for unbiased spatial discovery, at unprecedented speeds -Innovations include a novel spatial...

MARLBOROUGH, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (Nasdaq: AKYA), The Spatial Biology Company®, and PathAI, a global leader in artificial intelligence (AI)-powered...

The program will highlight the latest breakthroughs and applications in spatial biology and the company’s latest innovations to accelerate breakthroughs in discovery and clinical research. ...

MARLBOROUGH, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, today announced that new data generated with its CODEX® and Phenoptics™...